At a Glance
- Companies: Regeneron, Telix Pharmaceuticals
- Location: US/Australia
- Deal value: $2.1B biobucks (upfront + milestones)
- Focus area: Alpha-emitting radiopharma combos
- Next steps: IND filings, Phase I combo trials
What happened?
Regeneron Pharmaceuticals signed a $2.1 billion biobucks collaboration and licence agreement with Telix Pharmaceuticals to develop radiopharmaceuticals combining Regeneron’s biologics with Telix’s lead-212 (Pb-212) alpha-emitter platform. The pact grants Regeneron exclusive rights to pair its antibodies and proteins with Telix’s targeted radioconjugates.
Why does it matter?
Radiopharma represents a high-growth oncology modality, with alpha-emitters like Pb-212 offering potent tumour killing via high linear energy transfer while minimising range-related toxicity compared to beta-emitters. Pairing Regeneron’s industry-leading bispecifics and ADCs with Telix’s generator-derived Pb-212 could yield best-in-class theranostics, targeting solid tumours where checkpoint inhibitors and ADCs have reached efficacy plateaus.
Who’s behind it?
Regeneron brings its oncology portfolio including Libtayo (cemiplimab), PD1/VEGF bispecifics and next-gen IO/ADC assets. Telix contributes its clinical-stage Pb-212 platform (TLX-101CDx for glioma imaging/diagnostics already filed) and GMP supply chain for alpha-emitter chelation and delivery.
How was it achieved?
The deal leverages Telix’s proprietary Pb-212 generator technology — which decays actinium-228 to bismuth-212 then Pb-212 in minutes — enabling scalable, on-site production without costly cyclotrons. Preclinical synergy data likely demonstrated superior tumour penetration and bystander killing when conjugating Regeneron IO agents to Pb-212 versus cold antibodies or beta-radioconjugates.
What’s next?
The partners will prioritise prostate, glioblastoma and other solid tumours for combo development, targeting IND submissions in 2027 and first-in-human data by 2028. Telix receives upfront cash plus milestones tied to regulatory, clinical and commercial benchmarks; Regeneron gains global rights with Telix retaining co-promotion in select markets. Further pipeline expansion via Regeneron’s 30+ preclinical biologics is anticipated.